Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications

Medical Hypotheses

Volumn 73, Issue 2, 2009, Pages 259-262

  Conway, J L C ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE PATCH;

ADDICTION; APOPTOSIS; ARTICLE; BRAIN FUNCTION; CIGARETTE SMOKING; DELUSION; DYSTONIA; ELECTROPHYSIOLOGY; EXCITOTOXICITY; EXTRAPYRAMIDAL SYMPTOM; GENETICS; HABITUATION; HEALTH; HUMAN; HYPOTHESIS; MENTAL DISEASE; NARCOLEPSY; NEUROPHYSIOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF MEDICATION; SMOKING; SYMPTOM;

APOPTOSIS; HUMANS; NICOTINE; SCHIZOPHRENIA; SMOKING; SYNAPTIC TRANSMISSION;

NICOTIANA TABACUM;

EID: 67349256385     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.02.017     Document Type: Article

References (28)

1. Kuehn B.M. Link between smoking and mental illness may lead to treatments. J Am Med Assoc 295 (2006) 483-484
2. George T.P., Ziedonis D.M., Feingold A., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiat 157 11 (2000) 1835-1842
3. Leonard S., and Adams C.E. Smoking cessation in schizophrenia (images in neuroscience). Am J Psychiat 163 11 (2006) 1877
4. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiat 155 11 (1998) 1490-1501
5. Rezvani A.H., and Levin E.D. Cognitive effects of nicotine. Biol Psychiat 49 (2001) 258-267
6. In: Tamminga C.A. (Ed). Schizophrenia in a molecular age. Rev Psychiat 18 4 (1999) 12-14
7. Punnoose S., and Belgamwar M.R. Nicotine for schizophrenia (review). The Cochrane Collaboration (2006), Wiley and Sons, London
8. Ellis H., and Calne R.Y. Lecture notes on general surgery. 6th ed. (1984), Blackwell, Oxford
9. Kelly C., and McCreadie R.M. Smoking habits, current symptoms, and premorbid characteristics of schizophrenia patients in Nithsdale, Scotland. Am J Psychiat 156 11 (1999) 1751-1758
10. Hughes J.R., Hatsukami D.K., Mitchell J.E., and Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am J Psychiat 143 (1986) 993-997
11. McEvoy J.P., and Brown S. Smoking in first-episode patients with schizophrenia. Am J Psychiat 156 7 (1999) 1120-1122
12. Postma P., Kumari V., Hines M., and Gray J.A. The relationship between prepulse detection and prepulse inhibition of the acoustic startle reflex. Psychophysiology 38 (2001) 377-382
13. Leonard S., Breese C., Adams C., et al. Smoking and schizophrenia: abnormal nicotinic receptor expression. Europe J Pharmacol 393 (2000) 237-242
14. William Byne, Eileen Kemether, Liesl Jones, Vahram Hartounian, Kenneth L Davis. The neurochemistry of schizophrenia. In: Neurobiology of mental illness. 1st ed. New York: Oxford University Press; 1999.
15. Adler L.E., Olincy A., Waldo M., et al. Schizophrenia, sensory gating and nicotinic receptors. Schizophrenia Bullet 24 2 (1998) 189-202
16. Garcia-Anaya M., Apiquian R., and Fresán A. Sensory gating and P50: neurobiology implications for schizophrenia. Salud Ment 29/1 (2006) 64-70
17. Potter D., Summerfelt A., Gold J., and Buchanan R. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophrenia Bullet 32 4 (2006) 692-700
18. Croft R.J., Dimoska A., Gonsalvez C.J., and Clarke A.R. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiat Res 128 (2004) 53-62
19. Griffith J.M., O'Neill J.E., Petty F., Garver D., Young D., and Freedman R. Nicotinic receptor desensitisation and sensory gating deficits in schizophrenia. Biol Psychiat 44 (1998) 98-106
20. Deutsch S.I., Rosse R.B., Schwartz B.L., and Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24 1 (2001) 43-49
21. Mednick S.A., Huttunen M.O., and Machón R.A. Prenatal influenza infection and adult schizophrenia. Schizophrenia Bullet 20 2 (1994) 263-267
22. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophrenia Bullet 32 2 (2006) 200-202
23. Fredrik Jarskog L. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiat 19 3 (2006) 307-312
24. Patkar A.A., Gopalkrishnan R., Lundy A., Certa K.M., and Weinstein S.P. Relationship between tobacco smoking and positive and negative symptoms of schizophrenia. J Nerv Ment Disease 190 9 (2002) 605-610
25. Nomikos G.G., Schilström B., Hildebrand B.E., Panagis G., Grenhoff J., and Svensson T.H. Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behaviour Brain Res 113 1-2 (2000) 97-103
26. Rosse R.B., and Deutsch S.I. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25 5 (2002) 272-275
27. 7 nicotinic receptor abnormality in schizophrenia. Israel J Psychiat Relate Sci 42 (2005) 33-44
28. Chou K.R., Chen R., Lee J.F., Ku C.H., and Lu R.B. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Inter J Nursing Stud 41 3 (2004) 321-330